Investigating the applicability domain of the hiPSC-based PluriLum assay: an embryotoxicity assessment of chemicals and drugs

Andreas Frederik Treschow,Maria João Valente,Karin Lauschke,Bjørn Holst,Anders Reenberg Andersen,Anne Marie Vinggaard

DOI: https://doi.org/10.1007/s00204-023-03675-1

2024-02-05

Archives of Toxicology

Abstract:To meet the growing demand for developmental toxicity assessment of chemicals, New Approach Methodologies (NAMs) are needed. Previously, we developed two 3D in vitro assays based on human-induced pluripotent stem cells (hiPSC) and cardiomyocyte differentiation: the PluriBeat assay, based on assessment of beating differentiated embryoid bodies, and the PluriLum assay, a reporter gene assay based on the expression of the early cardiac marker NKX2.5 ; both promising assays for predicting embryotoxic effects of chemicals and drugs. In this work, we aimed to further describe the predictive power of the PluriLum assay and compare its sensitivity with PluriBeat and similar human stem cell-based assays developed by others. For this purpose, we assessed the toxicity of a panel of ten chemicals from different chemical classes, consisting of the known developmental toxicants 5-fluorouracil, all- trans retinoic acid and valproic acid, as well as the negative control compounds ascorbic acid and folic acid. In addition, the fungicides epoxiconazole and prochloraz, and three perfluoroalkyl substances (PFAS), PFOS, PFOA and GenX were tested. Generally, the PluriLum assay displayed higher sensitivity when compared to the PluriBeat assay. For several compounds the luminescence readout of the PluriLum assay showed effects not detected by the PluriBeat assay, including two PFAS compounds and the two fungicides. Overall, we find that the PluriLum assay has the potential to provide a fast and objective detection of developmental toxicants and has a level of sensitivity that is comparable to or higher than other in vitro assays also based on human stem cells and cardiomyocyte differentiation for assessment of developmental toxicity.

toxicology

What problem does this paper attempt to address?

The main objective of this paper is to further explore and validate a novel in vitro toxicity testing method based on human induced pluripotent stem cells (hiPSC) — the PluriLum assay, in terms of its applicability and sensitivity in assessing the embryotoxicity of chemicals and drugs.

Specifically, the research team developed two 3D in vitro testing systems, both based on hiPSC and cardiomyocyte differentiation: the PluriBeat assay and the PluriLum assay. The PluriLum assay is a reporter gene assay based on the expression of the early cardiac marker NKX2.5, and it is considered to have potential in predicting the toxicity of chemicals and drugs to embryos.

In this work, the researchers evaluated the predictive capability and sensitivity of the PluriLum assay compared to the PluriBeat assay by testing a set of 10 chemicals, including known developmental toxicants, negative control compounds, biocides, and perfluoroalkyl substances (PFAS). The results showed that the PluriLum assay generally exhibited higher sensitivity than the PluriBeat assay and was able to detect the effects of certain substances that were not observed in the PluriBeat assay.

In summary, the PluriLum assay has been demonstrated to have potential in rapidly and objectively detecting developmental toxicants, with a sensitivity level that can be comparable to or higher than other human stem cell-based cardiomyocyte differentiation developmental toxicity testing systems. This suggests that the PluriLum assay could become an effective alternative method to reduce the need for animal testing and improve the accuracy of predicting human responses.